

## AMENDMENTS TO THE CLAIMS

Claims 1-35

(Canceled)

Claim 36.

(Currently Amended) A chemically ~~synthesized~~ modified double stranded short interfering ~~nucleic~~ ribonucleic acid (siNA) (siRNA) molecule comprising a first sense strand and an second antisense strand ~~where the first strand is a sense strand and the second strand is an antisense strand~~, wherein:

- a. each strand of said ~~siNA~~ siRNA molecule is about 18 to about 27 nucleotides in length;
- b. the antisense strand of said ~~siNA~~ siRNA molecule comprises a about 18 to about 27 nucleotides sequence that is are complementary to a nucleotide sequence of platelet-derived endothelial cell growth factor (ECGF1) RNA and the sense strand is complementary to the antisense strand nucleotide sequence corresponding to SEQ ID NO:225 and are also complementary to the sense strand; and
- c. the sense strand of said siRNA molecule comprises a portion of said ECGF1 nucleotide sequence of about 18 to about 27 nucleotides; and
- d. said siNA siRNA molecule comprises at least one chemically modified nucleotide or non-nucleotide at the 5' end and/or 3' end of the sense strand and the 3' end of the antisense strand 2'-O-methyl or 2'-deoxy-2'-fluoro nucleotide.

Claim 37.

(Canceled)

Claim 38.

(Currently amended) The ~~siNA~~ siRNA molecule of claim 36, wherein said ~~siNA~~ siRNA molecule comprises one or more ribonucleotides.

Claim 39.

(Canceled)

- Claim 40. (Canceled)
- Claim 41. (Canceled)
- Claim 42. (Canceled)
- Claim 43. (Canceled)
- Claim 44. (Canceled)
- Claim 45. (Canceled)
- Claim 46. (Canceled)
- Claim 47. (Canceled)
- Claim 48. (Currently amended) The ~~siNA~~ siRNA molecule of claim 36, wherein said sense ~~region~~ strand is connected to the antisense ~~region~~ strand via a linker molecule.
- Claim 49. (Currently amended) The ~~siNA~~ siRNA molecule of claim 48, wherein said linker molecule is a polynucleotide linker.
- Claim 50. (Currently amended) The ~~siNA~~ siRNA molecule of claim 48, wherein said linker molecule is a non-nucleotide linker.
- Claim 51. (Currently amended) The ~~siNA~~ siRNA molecule of claim 36, wherein one or more pyrimidine nucleotides present in the sense ~~region~~ strand are 2'-O-methyl pyrimidine nucleotides.
- Claim 52. (Currently amended) The ~~siNA~~ siRNA molecule of claim 36, wherein one or more purine nucleotides present in the sense ~~region~~ strand are 2'-deoxy purine nucleotides.
- Claim 53. (Currently amended) The ~~siNA~~ siRNA molecule of claim 36, wherein one or more pyrimidine nucleotides present in the sense ~~region~~ strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides.

- Claim 54. (Currently amended) The ~~siNA~~ siRNA molecule of claim 47, wherein the ~~fragment comprising said sense region strand~~ includes a terminal cap moiety at the 5'-end, the 3'-end, or both of the 5' and 3' ends of the ~~fragment comprising said sense region strand~~.
- Claim 55. (Currently amended) The ~~siNA~~ siRNA molecule of claim 54, wherein said terminal cap moiety is an inverted deoxy abasic moiety.
- Claim 56. (Currently amended) The ~~siNA~~ siRNA molecule of claim 36, wherein one or more pyrimidine nucleotides of present in said antisense ~~region strand~~ are 2'-deoxy-2'-fluoro pyrimidine nucleotides.
- Claim 57. (Currently amended) The ~~siNA~~ siRNA molecule of claim 36, wherein one or more purine nucleotides of present in said antisense ~~region strand~~ are 2'-O-methyl purine nucleotides.
- Claim 58. (Currently amended) The ~~siNA~~ siRNA molecule of claim 36, wherein one or more purine nucleotides present in said antisense ~~region strand~~ comprise 2'-deoxy- purine nucleotides.
- Claim 59. (Currently amended) The ~~siNA~~ siRNA molecule of claim 56, wherein said antisense ~~region strand~~ comprises a phosphorothioate internucleotide linkage at the 3' end of said antisense ~~region strand~~.
- Claim 60. (Canceled)
- Claim 61. (Canceled)
- Claim 62. (Canceled)
- Claim 63. (Canceled)
- Claim 64. (Canceled)
- Claim 65. (Canceled)

Claim 66. (Canceled)

Claim 67. (Canceled)

Claim 68. (Currently amended) The ~~siNA~~ siRNA molecule of claim 47, wherein the 5'-end of ~~the fragment comprising~~ said antisense ~~region strand~~ optionally includes a terminal phosphate group.

Claim 69. (Currently amended) A ~~pharmaceutical~~ composition comprising the ~~siNA~~ siRNA molecule of claim 36 ~~in an~~ and a pharmaceutically acceptable carrier or diluent.